Objectives. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The aim of this analysis was to characterize changes in haematological parameters following tofacitinib treatment, and to compare changes in haemoglobin with markers of disease activity, fatigue and vitality.
Introduction
Active RA is associated with a number of haematological abnormalities, including increased levels of neutrophils in both SF [1] and blood [2] , and decreased T lymphocyte counts [3] . Anaemia, as defined by the WHO criteria (haemoglobin <12 g/dl in women and <13 g/dl in men), is also reported in 37% of patients with RA [4] .
Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of RA. The efficacy and safety of tofacitinib has been demonstrated in patients with moderate to severe active RA at doses of 5 and 10 mg bd in phase 2 [59] and phase 3 [1015] randomized controlled trials (RCTs) of up to 24 months' duration, and in long-term extension (LTE) studies of up to 96 months' observation [16] .
Tofacitinib preferentially inhibits signalling by receptors associated with JAK1 and JAK3, with functional selectivity over JAK2 [17, 18] . JAKs are a subgroup of protein tyrosine kinases required for types I and II cytokine receptor signalling. Inhibition of JAK1 and JAK3 blocks signalling through the receptors for several cytokines, including pro-inflammatory cytokines, thereby disrupting inflammatory processes, resulting in improved clinical outcomes in patients with RA.
Decreases in neutrophil counts have been reported across phase 2 studies of tofacitinib in RA, together with decreases in haemoglobin, some of which have been clinically meaningful (>2 g/dl) [19] . In a 12-week study assessing the effect of tofacitinib on haematological parameters in patients with psoriasis, dose-dependent decreases in neutrophil and red blood cell counts, and increases in lymphocyte counts, were observed [20] . These effects were not progressive, and were often transient or reversible.
Given the importance of JAK2 signalling in erythropoiesis and the involvement of JAK1 and JAK3 in lymphoid development [21, 22] , it was deemed important to evaluate the effects of tofacitinib on haematological parameters over a longer treatment duration. The objectives of this analysis were to characterize changes in neutrophil and lymphocyte counts and haemoglobin levels following tofacitinib treatment in patients with RA pooled from phase 3 RCTs and LTE studies.
Methods

Patients
Eligibility criteria
Patients were eligible for phase 3 trials if they were 518 years of age, with moderate to severe active RA based on the ACR 1987 criteria. Patients were excluded if they had: suffered a significant infection within the previous 6 months; haematopoietic disorders; a haemoglobin level <9 g/dl; a haematocrit <30%; a white blood cell count <3.0 Â 10 3 /mm 3 ; an absolute neutrophil count <1.2 Â 10 3 /mm 3 ; an absolute lymphocyte count <0.5 Â 10 3 /mm 3 ; evidence of untreated or inadequately treated Mycobacterium tuberculosis infection; recurrent herpes zoster or disseminated herpes simplex virus infections; infection with human immunodeficiency virus, hepatitis B or hepatitis C; or a history of, or existing, malignancy (other than adequately treated or excised nonmetastatic skin cancer or cervical carcinoma in situ). Patients enrolling in the LTE study >14 days after completing a qualifying study were rescreened based on the criteria above, with the exception that patients in Korea, Croatia, Denmark, Czech Republic, Germany, Spain, Sweden, Ireland and the UK were excluded if they had an absolute lymphocyte count of <0.75 Â 10 3 /mm 3 .
Study design
The phase 3 population comprised patients from six multicentre, double-blind RCTs of 624 months' duration. Tofacitinib was dosed at 5 or 10 mg bd as monotherapy (ORAL Solo, NCT00814307 [11] ; ORAL Start, NCT01039688, no placebo arm [13] ) or in combination with conventional synthetic DMARDs (csDMARDs), mainly MTX (ORAL Scan, NCT00847613 [14] ; ORAL Step, NCT00960440 [10] ; ORAL Sync, NCT00856544 [12] ; ORAL Standard, NCT00853385 [15] [23] ) enrolled patients who had participated in prior phases 1, 2 or 3 qualifying index studies of tofacitinib. Regardless of treatment assignment in the qualifying index study, patients enrolling from phase 1 and 2 studies initiated treatment in the LTE studies with tofacitinib 5 mg bd, and those enrolling from phase 3 studies initiated treatment with tofacitinib 10 mg bd (with the exception of Chinese and Japanese patients who initially received 5 mg bd). Dose adjustments of tofacitinib and background csDMARD therapy were permitted based on the investigator's assessment of efficacy and safety. To classify patients into 5 or 10 mg bd treatment groups, the average total daily dose of tofacitinib was calculated by adding all doses received by each patient, and dividing by the number of days a dose was received. Patients were assigned to the 5 mg bd group if the total daily dose was <15 mg/day, and to the 10 mg bd group if it was 515 mg/day. Baseline values were those of the qualifying study for patients who enrolled in the LTE studies within 14 days of the final visit of the qualifying study; for other patients, baseline values were derived from the final predrug visit on entry into the LTE studies. Baseline values were those of the qualifying studies for $91% of patients.
All studies were conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines established by the International Conference on Harmonization. The final protocols, amendments and informed consent documentation were reviewed and approved by the Institutional Review Boards and/or Independent Ethics Committee of each study centre. All patients provided written, informed consent.
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Outcomes and objectives
The primary objective of this analysis was to determine changes in haematological parameters (neutrophil and lymphocyte counts plus haemoglobin levels) in patients receiving tofacitinib 5 or 10 mg bd, placebo or active comparators in the phase 3 studies and in patients receiving either tofacitinib dose in the LTE studies. The secondary objectives were to assess the incidence of anaemia (as defined by the OMERACT criteria [24] ) and to compare changes in haemoglobin with changes in disease activity, fatigue and vitality. Disease activity was assessed using ESR and CRP level. Fatigue and vitality were assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Medical Outcomes Survey Short Form Health Survey (SF)-36 vitality domain (higher scores indicate improvement). Safety and outcome measures data were collected at each study visit for up to 24 months in phase 3 studies, and 84 months in LTE studies. Results summarized by visit for each treatment group are presented for time points at which the number of patients was greater than 100.
Statistical analysis
Data for each treatment arm were pooled across all phase 3 or LTE studies. Descriptive statistics of neutrophil count, lymphocyte count, haemoglobin, fatigue and vitality levels were analysed by treatment group. Exposure-adjusted event rates for anaemia were calculated as the number of unique patients with an event (for that time period) per 100 patient-years (PY) of study drug exposure. Exposure estimates and incidence rates for confirmed cases of neutropenia, lymphopenia and decreased haemoglobin were calculated similarly, but individual exposure was censored at the first occurrence of the event. Percentage decreases from baseline in haemoglobin, ESR and CRP at month 3 were compared relative to tertiles of haemoglobin or ESR. Tertiles were calculated based on the overall percentage change from baseline in either haemoglobin or ESR across all treatment groups. To determine the strength of the linear relationship between haemoglobin levels and FACIT-F or SF-36 vitality scores post baseline, a simple linear regression model was fitted and correlation coefficients were derived; correlation coefficients ranged from À1 to +1, with a value of 0 indicating no linear relationship, while values further from 0 indicated stronger positive or negative linear relationships. All P-values are shown for exploratory purpose; P < 0.05 was considered statistically significant.
Results
Patients
This analysis included 4271 phase 3 study patients. Of these, 1589 patients initiated treatment with tofacitinib 5 mg bd, 1611 tofacitinib 10 mg bd, 681 placebo, 204 adalimumab and 186 MTX. Placebo-treated patients advanced to tofacitinib 5 (n = 343) or 10 mg (n = 338) bd treatment after 3 or 6 months. Patient demographics were similar across treatment groups ( Table 1) .
The LTE studies enrolled 4858 patients: 1451 received tofacitinib 5 mg bd and 3407 received 10 mg bd. Patient demographics were similar across treatment groups, with the exception that the tofacitinib 5 mg bd group had a smaller proportion of Caucasian patients and greater proportion of Asian patients compared with the 10 mg bd group (Table 1) .
Neutrophil counts
Phase 3 studies
After 24 months of treatment, mean (S.E.) changes from baseline in neutrophil counts were À1.09 Â 10
LTE studies
After the initial decrease in the phase 3 studies, mean neutrophil counts remained relatively stable for up to 66 and 48 months for patients receiving tofacitinib 5 and 10 mg bd, respectively, in the LTE studies, with no evidence of dose response (Fig. 1B) . More variation was seen in patients receiving tofacitinib 10 mg bd beyond month 42 due to the low sample size for this group at later time points. No confirmed cases of clinically meaningful neutropenia were reported in patients receiving either tofacitinib dose (Table 2 ).
Lymphocyte counts
Phase 3 studies
Small increases in mean lymphocyte counts were seen after 3 months of treatment with both tofacitinib 5 and 10 mg bd, following which mean counts decreased progressively. After 24 months of treatment, mean changes from baseline in lymphocyte counts were À0.24 Â 10 3 /mm 3 (0.03) and À0.36 Â 10 3 /mm 3 (0.03) with tofacitinib 5 and 10 mg bd, respectively. Mean lymphocyte counts for patients receiving placebo for the first 6 months in phase 3 studies remained virtually unchanged from baseline ( Fig.  2A) . Patients receiving adalimumab showed a rapid increase in mean lymphocyte count to 0.35 Â 10 3 /mm 3 (0.04) above baseline at month 3, which then remained stable over 12 months of treatment ( Fig. 2A) . Patients receiving MTX showed a decrease in mean lymphocyte count, with a reduction from baseline of À 0.20 Â 10 3 /mm 3 (0.07) at month 24 ( Fig. 2A) .
LTE studies
After the initial reduction seen during the first 24 months in phase 3 studies, mean lymphocyte counts showed further gradual reductions for up to 48 months with both tofacitinib doses (Fig. 2B) . A dose response was observed, with greater reductions in mean lymphocyte count with tofacitinib 10 mg bd, compared with 5 mg bd. Beyond month 48, the mean lymphocyte count stabilized for the 5 mg bd group and across all tofacitinib doses. In the pooled data of the phase 3 and LTE studies, <1.0% (n = 37) of patients who received tofacitinib experienced clinically meaningful lymphopenia (absolute lymphocyte count [ALC] <0.5 Â10 3 /mm 3 ) ( Table 2 ).
The majority (92%) of these patients had lymphopenia (<1.5 Â 10 3 /mm 3 ) before tofacitinib initiation, and for those who had ALC follow-up values, ALC increased after tofacitinib discontinuation for most patients (84% of the subjects achieved ALC 50.5 Â 10 3 /mm 3 , and 45% of these subjects returned to within 20% of their respective baseline values).
Haemoglobin levels
Phase 3 studies
By 24 months, the mean (S.E.) increases from baseline in haemoglobin level were 0.47 g/dl (0.05) and 0.28 g/dl (0.05) with tofacitinib 5 and 10 mg bd, respectively (Fig. 3A) . There was very little change from baseline in haemoglobin levels for patients receiving placebo up to month 6 (À0.01 g/dl [0.06]). MTX-treated patients had a mean increase from baseline in haemoglobin of 0.30 g/dl (0.11) at month 24, and adalimumab-treated patients had a mean increase in baseline of 0.46 g/dl (0.09) at month 12.
The proportions of patients with decreased haemoglobin levels over 24 months were similar between patients receiving tofacitinib, MTX and placebo (Table 2) . A smaller proportion in the adalimumab-treated group had decreased haemoglobin levels, with no patients experiencing a decrease in haemoglobin of >2 g/dl from baseline or an absolute haemoglobin level of <8 g/dl. Clinically meaningful decreases in haemoglobin (decrease from baseline of 53 g/dl or an absolute haemoglobin level of 47 g/dl [25] ) were observed in <1.0% of patients who received either tofacitinib 5 mg or 10 mg bd and in 1.1% of patients treated with MTX (Table 2) .
LTE studies
In the LTE study, changes from baseline in haemoglobin were generally stable for up to 66 months with tofacitinib 5 mg bd and for up to 48 months with 10 mg bd (Fig. 3B) . Similar proportions of patients with decreased haemoglobin were observed with tofacitinib 5 and 10 mg bd, with clinically meaningful haemoglobin changes in <2% of all patients receiving tofacitinib ( Table 2) .
Incidence of anaemia
Exposure-adjusted rates of anaemia (number of patients with the event per 100 PY of drug exposure) for the tofacitinib 5 or 10 mg bd, placebo and MTX treatment groups up to month 3 were 1.09, 0.89, 1.34 and 0.75, respectively, and from months 36 were 0.36, 0.92, 0.43 and 0.37, respectively (supplementary Table S1 , available at Rheumatology Online). Post month 6, exposure-adjusted Table S1 , available at Rheumatology Online).
Relationship between haemoglobin changes and markers of RA disease activity At month 3, increases from baseline in haemoglobin were associated with decreases in ESR and CRP level from baseline in tofacitinib-treated patients (Fig. 4) . ESR decreased in all patients treated with tofacitinib; however, patients with the greatest increases from baseline in
FIG. 1 Mean neutrophil count over time (A) Phase 3 studies. (B) LTE studies. Dashed lines in the LTE studies indicate
that baseline values were those of the qualifying index study for patients who enrolled within 14 days of the final visit of the qualifying study; other patients were rescreened, and baseline values were derived on entry into the LTE studies; 91% of baseline values were from the index study. Data are presented to month 48 for the tofacitinib 10 mg bd group due to the low number of patients remaining in the study after this time point. LTE: long-term extension; q2w: once every 2 weeks.
TABLE 2
Proportion of patients and incidence rate for confirmed neutropenia, lymphopenia and decreased haemoglobin in phase 3 studies over 24 months and LTE studies over 84 months www.rheumatology.oxfordjournals.org haemoglobin levels (i.e. those in the third tertile) had the greatest reduction from baseline in ESR for both doses. CRP showed a similar trend; however, in patients with decreases from baseline in haemoglobin level (i.e. those in the first tertile), CRP levels were increased from baseline, and were then progressively reduced below baseline levels in patients with increases in haemoglobin above baseline (i.e. those in the second and third tertile). In placebo-treated patients, a similar pattern of changes in ESR and CRP were observed that generally matched changes in haemoglobin; however, ESR and CRP levels did not decrease substantially below baseline levels in any tertile. Similar trends were observed when haemoglobin, ESR and CRP levels were compared between patients relative to ESR tertiles; i.e., the greatest increases in ESR were associated with the greatest decreases in haemoglobin and increases in CRP (data not shown).
FIG. 2 Mean lymphocyte count over time
(A) Phase 3 studies. (B) LTE studies. Dashed lines in the LTE studies indicate that baseline values were those of the qualifying index study for patients who enrolled within 14 days of the final visit of the qualifying study; other patients were rescreened, and baseline values were derived on entry into the LTE studies; 91% of baseline values were from the index study. Data are presented to month 48 for the tofacitinib 10 mg bd group due to the low number of patients remaining in the study after this time point. LTE: long-term extension; q2w: once every 2 weeks.
FIG. 3 Mean haemoglobin changes over time
Relationship between haemoglobin changes and fatigue and vitality It has previously been reported in phase 3 studies that patients receiving tofacitinib 5 or 10 mg bd, MTX and adalimumab reported greater improvements in FACIT-F and SF-36 vitality scores from baseline compared with those receiving placebo [2628] . Here the correlation between these measures of fatigue and vitality and haemoglobin levels was evaluated. Although some significant positive correlations were reported between decreases in fatigue (i.e. increased FACIT-F score) and increases from baseline in haemoglobin level for all treatment groups, these correlations were generally weak (correlation coefficient <0.3) and do not provide evidence for an association between haemoglobin changes and fatigue in these clinical studies (supplementary Table S2 , available at Rheumatology Online). Similarly, weak correlations were observed between increased vitality and increased haemoglobin levels, which do not provide evidence for an association between these measures (supplementary Table S3 , available at Rheumatology Online).
Discussion
This analysis characterized changes in haematological parameters in patients with RA in phase 3 and LTE studies in the tofacitinib clinical development programme. Decreases were observed in mean neutrophil counts in the early months of tofacitinib treatment, before stabilizing in the LTE studies. Mean lymphocyte counts increased slightly in the first 3 months of treatment with either dose of tofacitinib, and thereafter progressively decreased in the phase 3 studies. A further gradual decrease was observed up to month 48 in the LTE studies with both tofacitinib doses and then stabilized. Tofacitinib treatment resulted in increases in haemoglobin levels; greater increases were observed with tofacitinib 5 mg bd compared with 10 mg bd. Mean haemoglobin levels were relatively stable in the LTE studies for up to 66 months. However, caution should be exercised in interpreting these findings, as relatively few patients were included at later time points in the LTE studies.
Decreases in haemoglobin levels and incidence of anaemia were infrequent in all treatment groups, and clinically meaningful reductions in haemoglobin levels were similar between tofacitinib 5 and 10 mg bd, placebo and MTX treatments. However, given the smaller number of patients in the adalimumab and MTX treatment groups, comparisons between active treatments should be interpreted with caution. Changes in haemoglobin levels were paralleled by changes in the opposite direction in markers of RA disease activity. Changes in measures of fatigue and vitality were not associated with changes in haemoglobin levels.
Previous phase 2 studies of tofacitinib for RA and psoriasis have reported dose-dependent decreases in neutrophil counts [19, 20] . The current study confirmed these findings, but also demonstrated that little further decrease was seen beyond that observed in these relatively shortterm phase 2 studies, and neutrophil counts stabilized with long-term tofacitinib treatment. The initial transient increase in mean lymphocyte count seen in the present study was also seen in the 12-week study of tofacitinib in psoriasis [20] . Thereafter the mean change from baseline in absolute lymphocyte counts decreased gradually and then stabilized at month 48. The decreased mean change in lymphocyte count in the tofacitinib 10 mg bd group appeared slightly greater than in the 5 mg bd group (0.1À0.2 Â 10 3 /mm 3 ). Tofacitinib inhibits JAK-dependent IL-6 signalling, which is involved in neutrophil activation, and this may be the mechanism by which tofacitinib reduces circulating neutrophil numbers [20, 21, 29, 30] . This is consistent with studies indicating that the antiIL-6 receptor mAb tocilizumab reduces circulating neutrophil counts in patients with RA [31] . However, treatment with adalimumab, a TNF inhibitor, also resulted in a similar level of reduction in mean neutrophil count when compared with tofacitinib over 12 months. Therefore, the decrease in neutrophils may be due to more general anti-inflammatory effects, involving multiple pathways. Evidence of JAK1 and JAK3 involvement in lymphoid development has also been reported [22] , suggesting a potential mechanism by which tofacitinib induces changes in lymphocytes and neutrophils.
Stable haemoglobin levels for up to 24 weeks with tofacitinib 2 and 5 mg bd, but decreases in haemoglobin with higher doses (15 mg bd), have been reported in the RA and psoriasis phase 2 studies [19, 20] . In the current pooled analysis from phase 3 and LTE studies, increases in haemoglobin were observed initially with both tofacitinib 5 and 10 mg bd; levels stabilized over time. These data indicate that tofacitinib does not significantly inhibit the JAK2-dependent pathways that are critical for erythropoiesis [21, 22] , and that any decreases in erythropoiesis as a result of JAK2 inhibition are outweighed by improvements in erythropoiesis secondary to the reduction in systemic inflammation as a result of tofacitinib treatment. This is also supported by the inverse relationship observed between disease activity markers and haemoglobin levels, in line with findings from other studies [32, 33] . The similar trend for placebo-treated patients, although with smaller magnitude of changes, suggests that haemoglobin levels are associated with inflammatory markers irrespective of RA treatment. This is likely due to the similar signalling pathways and molecules involved in haematopoiesis and inflammation [3436] .
Fatigue and vitality were assessed because these symptoms have been reported by 4080% of patients with RA, are often described by patients as one of their most disabling symptoms [3740] , and because OMERACT has recently recommended that fatigue is reported as a secondary outcome in clinical studies of RA [38, 41] . Across the tofacitinib clinical development programme, improvements in vitality and reductions in fatigue have been reported using the SF-36 and FACIT-F assessments [26, 42] . The data presented here suggest that fatigue is only weakly associated with haemoglobin changes in RA, but that haemoglobin changes are linked to changes in markers of disease activity. Other studies have also found no association between fatigue and haemoglobin levels or anaemia [40, 43] . The weak association between fatigue and haemoglobin changes is likely due to the multifactorial nature of fatigue, which is related to disease processes alongside cognitive, behavioural and personal dimensions [4447] .
Strengths of this study were the large population size and the long duration of tofacitinib exposure in the LTE studies. However, interpretation of results in the LTE studies was limited because the results may be biased due to the selected patient population in the LTE studies who could tolerate tofacitinib long term. In addition, there were no active or placebo comparator groups in the LTE studies, and dose adjustments of tofacitinib could be made, which limits dose comparisons. In the phase 3 studies, patient demographics and characteristics were similar, allowing comparison of different treatments between groups. However, there was limited exposure to active and placebo comparators compared with tofacitinib.
In summary, treatment with tofacitinib 5 and 10 mg bd resulted in decreased mean neutrophil counts, which generally stabilized during LTE studies. Treatment with tofacitinib resulted in a gradual reduction in mean lymphocyte count, which appeared to stabilize over time. Tofacitinib treatment at both doses resulted in increases in haemoglobin levels, which then stabilized for up to 66 months. Cases of clinically meaningful reductions in haemoglobin and incidence of anaemia were low, and similar to placebo and MTX. Although tofacitinib treatment resulted in reductions in fatigue and improvements in vitality, these were largely independent of changes in haemoglobin.
